Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes
Semiglazova, T.Iu.; Gershanovich, M.L.
Voprosy Onkologii 47(3): 298-302
2001
ISSN/ISBN: 0507-3758 PMID: 11544827 Document Number: 538154
Xeloda (capecetabine) has been tested for efficacy and toxicity in treating disseminated breast cancer after the potential of anthracycline (group 1) chemotherapy, anthracyclines plus taxanes (group 2) was exhausted. The patients included into the study (54) were divided into groups 1 (33) and 2 (21). Apparent response was in 24 and 21%, respectively. The drug may be used both in out-patients and those refractory to anthracycline chemotherapy and anthracyclines plus taxanes due to moderate toxicity, slight myelodepression and absence of alopecia which seldom makes treatment useless.